Q3 2024 Earnings Call Nov 06, 2024, 4:30 p.m. ET. Contents: Prepared Remarks. Questions and Answers. Call Participants.

On Friday, Gilead Sciences, Inc. (GILD) stock saw a decline, ending the day at $96.57 which represents a decrease of $-1.33 or -1.36% from the prior close of $97.9. The stock opened at $96.05 and ...

Gilead Sciences Canada, Inc. (Gilead Canada) announced today that Paul Petrelli joined the organization as Vice President and ...

Despite a mission to become a dominant cancer drug player, Gilead Sciences has as of late been locked in on its ...

In his new role, Petrelli will be responsible for leading the commercial organization for Gilead Canada, with a focus on ...

Q3 2024 Earnings Conference Call November 6, 2024 4:30 PM ETCompany ParticipantsDaniel O'Day - Chairman, Chief ...

Gilead Sciences, Inc. (NASDAQ:GILD ... The speakers on today's call will be our Chairman and Chief Executive Officer, Daniel O'Day; our Chief Commercial Officer, Johanna Mercier; our Chief Medical ...

Presentation Operator Good afternoon, everyone, and welcome to Gilead's Third Quarter 2024 Earnings Conference Call. My name ...

BMO Capital Markets analyst Evan Seigerman in a note to investors called Gilead’s third-quarter performance “consistent” and ...

Piper Sandler raised the firm’s price target on Gilead (GILD) to $105 from $95 and keeps an Overweight rating on the shares. The firm ...

On Thursday, Gilead Sciences, Inc. (GILD) stock saw a modest uptick, ending the day at $97.9 which represents a slight increase of $6.21 or 6.77% from the prior close of $91.69. The stock opened at ...